Pharmacokinetics and pharmacodynamics of injectable testosterone undecanoate in castrated cynomolgus monkeys (Macaca fascicularis) are independent of different oil vehicles

@article{Wistuba2005PharmacokineticsAP,
  title={Pharmacokinetics and pharmacodynamics of injectable testosterone undecanoate in castrated cynomolgus monkeys (Macaca fascicularis) are independent of different oil vehicles},
  author={Joachim Wistuba and C. Marc Luetjens and Axel Kamischke and Yi-qun Gu and Stefan Schlatt and Manuela Simoni and Eberhard Nieschlag},
  journal={Journal of Medical Primatology},
  year={2005},
  volume={34}
}
Abstract:  Testosterone undecanoate (TU) dissolved in soybean oil was developed in China to improve the pharmacokinetics of this testosterone ester in comparison with TU in castor or tea seed oil. As a pre‐clinical primate model, three groups of five castrated cynomolgus macaques received either a single intramuscular injection of 10 mg/kg bodyweight TU in soybean oil, in tea seed oil, or in castor oil (equals 6.3 mg pure T/kg bodyweight for all preparations). Testosterone, estradiol… 
View on Wiley
cbpmedia.cbp.pitt.edu
9 Citations
Methods Citations
1

9 Citations

Citation Type

Citation Type

Testosterone Therapy: Injectable Androgens
TLDR
Available since 2004, testosterone undecanoate is an injectable testosterone preparation with a considerably better pharmacokinetic profile that reverses the effects of hypogonadism on bone and muscle and significantly improves metabolic parameters and sexual functions, without the “roller coaster” effects of traditional testosterone injections.
Testosterone-Induced Prostate Growth Is Blocked by Co- and Preadministration of Norethisterone Enanthate in Castrated Cynomolgus Monkeys
TLDR
Pre- and coadministration of NET reduces testosterone-induced prostate growth with possible implications for the treatment of benign prostate hyperplasia and hormonal male contraception.
Long-acting testosterone undecanoate for parenteral testosterone therapy
TLDR
Testosterone undecanoate is a new injectable testosterone preparation with a considerably better pharmacokinetic profile and Plasma testosterone levels with this preparation are almost always in the normal range.
Experimental endocrine manipulation by contraceptive regimen in the male marmoset (Callithrix jacchus).
TLDR
Male marmosets showed a different response to regimens of male contraception from macaques or men and have to be considered as a problematic model for preclinical trials of male hormonal contraception.
Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
TLDR
Testosterone substitution with im TU is generally well tolerated and modifications of androgen action are due to both AR CAG repeats and testosterone levels, and risk calculations for obese patients and nonlinear pharmacogenetic models to tailor androgen substitution are presented.
Orchidectomized (orx) marmoset (Callithrix jacchus) as a model to study the development of osteopenia/osteoporosis
TLDR
It is concluded that castration of young male marmoset for 1 year results in a significant loss of bone mineral density in the metaphysis of the tibia resulting in osteopenia but not in the vertebra, and male orx marmosets become osteopenic within 12 months after castration.
The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic Cancers
TLDR
It is reported for the first time that the aminosteroid derivative RM-133, developed in the laboratory, displays promising activity on two models of aggressive cancers, namely ovarian (OVCAR-3) and pancreatic (PANC-1) cancers.
The Leydig Cell as a Target for Male Contraception
TLDR
Control of testicular steroidogenesis and gametogenesis represents the main target of hormonal male contraception and hormonal fertility regulation through the Leydig cell provides the most promising method for men who wish to control their fertility.
Critical Factors Influencing the In Vivo Performance of Long-acting Lipophilic Solutions—Impact on In Vitro Release Method Design
TLDR
Parenteral long-acting lipophilic solutions have been used for decades and might in the future be used in the design of depots with tailored delivery characteristics, and the capability of in vitro release data to predict the in vivo performance of drug substances administrated in the form of lipophile solutions is discussed.

References

SHOWING 1-10 OF 47 REFERENCES
Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate.
TLDR
Testosterone levels reached the lower limit of normal after 31 days in two groups of five long-term orchidectomized cynomolgus monkeys which received a single intramuscular injection of an injectable testosterone undecanoate (TU) preparation or testosterone enanthate (TE) in a preclinical study to assess the pharmacokinetic and pharmacodynamic characteristics of TU in comparison to TE.
Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.
TLDR
The longer half-life and the smaller injection volume make TU in castor oil a strong candidate for further applications in substitution therapy and in trials for male contraception.
Pharmacokinetics and degree of aromatization rather than total dose of different preparations determine the effects of testosterone: a nonhuman primate study in Macaca fascicularis.
TLDR
The pattern of exposure and degree of aromatization rather than overall exposure to T determine its effects in the preclinical primate model, and both fluctuations of androgen concentrations and the conversion rate to estradiol influence gonadal suppression as well as metabolism.
New injectable testosterone ester maintains serum testosterone of castrated monkeys in the normal range for four months.
TLDR
It appears that the 20 Aet-1 may provide a long desired, new modality of testosterone substitution for hypogonadal men as well as for methods of male fertility control.
Estradiol and high-dose dihydrotestosterone treatment causes changes in cynomolgus monkey prostate volume and histology identical to those caused by testosterone alone.
TLDR
Both androgens fully restored prostate volume and ejaculatory function and an additional stimulatory effect of normal or slightly elevated estrogens on the prostate cannot be found in the presence of highly supraphysiological DHT levels.
Testosterone-induced inhibition of spermatogenesis is more closely related to suppression of FSH than to testicular androgen levels in the cynomolgus monkey model (Macaca fascicularis).
TLDR
It is concluded that pronounced suppression of primate spermatogenesis seemingly requires inhibition of FSH rather than testicular androgen levels, at least in this preclinical non-human primate model, for the purpose of male contraception.
A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men.
TLDR
It is concluded that both dosages of TU can effectively, safely, and reversibly suppress spermatogenesis in normal Chinese men.
Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates.
TLDR
In conclusion, androgen substitution with dihydrotestosterone-enanthate, in equivalent doses, is as effective as testosterone- enanthate in restoring reproductive functions in hypogonadal monkeys.
Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
TLDR
Compared with conventional testosterone enanthate or cypionate treatment requiring injection intervals of 2-3 weeks and resulting in supraphysiological serum testosterone levels, injections of TU at intervals of up to 3 months offer an excellent alternative for substitution therapy of male hypogonadism.
Hydrogenated soybean oil (HSO) as a vehicle for the chronic and controlled administration of testosterone in the orchidectomized rat.
...
1
2
3
4
5
...